Toll Free: 1-888-928-9744
Published: Feb, 2014 | Pages:
38 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Lupin Limited - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Lupin Limited - Product Pipeline Review - 2014', provides an overview of the Lupin Limited's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Lupin Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Lupin Limited including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Lupin Limited's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Lupin Limited's pipeline products Reasons to buy - Evaluate Lupin Limited's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Lupin Limited in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Lupin Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Lupin Limited and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lupin Limited - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Lupin Limited and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Lupin Limited Snapshot 5 Lupin Limited Overview 5 Key Information 5 Key Facts 5 Lupin Limited - Research and Development Overview 6 Key Therapeutic Areas 6 Lupin Limited - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Combination Treatment Modalities 11 Lupin Limited - Pipeline Products Glance 12 Lupin Limited - Late Stage Pipeline Products 12 Phase III Products/Combination Treatment Modalities 12 Lupin Limited - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Lupin Limited - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Discovery Products/Combination Treatment Modalities 15 Lupin Limited - Drug Profiles 16 (budesonide + formoterol fumarate + tiotropium bromide) 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Biosimilar for Cancer 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 LND-101001 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Biosimilar for Inflammation 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Biosimilar for Osteoporosis 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Biosimilar for Rheumatoid Arthritis 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Biosimilar for Viral Infections 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Small Molecule for Auto-Immune Diseases 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Small Molecule for Cancer 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Small Molecule for Diabetes 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Small Molecule for Pain and Inflammation 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Small Molecule for Viral Infections 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Lupin Limited - Pipeline Analysis 28 Lupin Limited - Pipeline Products by Target 28 Lupin Limited - Pipeline Products by Route of Administration 29 Lupin Limited - Pipeline Products by Molecule Type 30 Lupin Limited - Pipeline Products by Mechanism of Action 31 Lupin Limited - Dormant Projects 32 Lupin Limited - Company Statement 33 Lupin Limited - Locations And Subsidiaries 34 Head Office 34 Other Locations & Subsidiaries 34 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 38 Disclaimer 38
List of Tables Lupin Limited, Key Information 5 Lupin Limited, Key Facts 5 Lupin Limited - Pipeline by Indication, 2014 8 Lupin Limited - Pipeline by Stage of Development, 2014 9 Lupin Limited - Monotherapy Products in Pipeline, 2014 10 Lupin Limited - Combination Treatment Modalities in Pipeline, 2014 11 Lupin Limited - Phase III, 2014 12 Lupin Limited - Phase II, 2014 13 Lupin Limited - Preclinical, 2014 14 Lupin Limited - Discovery, 2014 15 Lupin Limited - Pipeline by Target, 2014 28 Lupin Limited - Pipeline by Route of Administration, 2014 29 Lupin Limited - Pipeline by Molecule Type, 2014 30 Lupin Limited - Pipeline Products by Mechanism of Action, 2014 31 Lupin Limited - Dormant Developmental Projects,2014 32 Lupin Limited, Other Locations 34 Lupin Limited, Subsidiaries 35
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.